Net Income (Loss) Attributable to Parent of Akari Therapeutics Plc from 31 Dec 2010 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Akari Therapeutics Plc quarterly and annual Net Income (Loss) Attributable to Parent in USD history and change rate from 31 Dec 2010 to 30 Sep 2025.
  • Akari Therapeutics Plc Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was $6,400,000, a 121% decline year-over-year.
  • Akari Therapeutics Plc Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was $15,772,000, a 22% increase year-over-year.
  • Akari Therapeutics Plc annual Net Income (Loss) Attributable to Parent for 2024 was $19,791,000, a 98% decline from 2023.
  • Akari Therapeutics Plc annual Net Income (Loss) Attributable to Parent for 2023 was $10,008,000, a 24% increase from 2022.
  • Akari Therapeutics Plc annual Net Income (Loss) Attributable to Parent for 2022 was $13,088,717, a 25% increase from 2021.
Source SEC data
View on sec.gov
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Akari Therapeutics Plc Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $15,772,000 $6,400,000 -$3,505,000 -121% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $12,267,000 $1,895,000 +$5,663,000 +75% 01 Apr 2025 30 Jun 2025 10-Q 13 Nov 2025 2025 Q3
Q1 2025 $17,930,000 $3,705,000 +$1,861,000 +33% 01 Jan 2025 31 Mar 2025 10-Q 13 Nov 2025 2025 Q3
Q4 2024 $19,791,000 $3,772,000 +$366,000 +8.8% 01 Oct 2024 31 Dec 2024 10-K 15 Apr 2025 2024 FY
Q3 2024 $20,157,000 $2,895,000 -$24,000 -0.84% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $20,133,000 $7,558,000 -$3,558,000 -89% 01 Apr 2024 30 Jun 2024 10-Q 13 Nov 2025 2025 Q3
Q1 2024 $16,575,000 $5,566,000 -$6,567,000 -656% 01 Jan 2024 31 Mar 2024 10-Q 13 Nov 2025 2025 Q3
Q4 2023 $10,008,000 $4,138,000 01 Oct 2023 31 Dec 2023 10-K 15 Apr 2025 2024 FY
Q3 2023 $2,871,000 01 Jul 2023 30 Sep 2023 10-Q 19 Nov 2024 2024 Q3
Q2 2023 $4,000,000 +$1,679,978 +30% 01 Apr 2023 30 Jun 2023 10-Q 19 Nov 2024 2024 Q3
Q1 2023 $1,001,000 01 Jan 2023 31 Mar 2023 10-Q 19 Nov 2024 2024 Q3
Q2 2022 $5,679,978 -$1,333,643 -31% 01 Apr 2022 30 Jun 2022 6-K 27 Sep 2022 2022 Q2
Q2 2021 $4,346,335 +$3,093,480 +42% 01 Apr 2021 30 Jun 2021 6-K 27 Sep 2022 2022 Q2
Q4 2020 $17,081,617 $6,809,849 +$1,020,176 +13% 01 Oct 2020 31 Dec 2020 20-F 01 May 2023 2022 FY
Q3 2020 $18,101,793 $913,454 +$3,795,348 01 Jul 2020 30 Sep 2020 20-F 21 Apr 2021 2020 FY
Q2 2020 $21,897,141 $7,439,815 -$1,492,042 -25% 01 Apr 2020 30 Jun 2020 6-K 22 Sep 2021 2021 Q2
Q1 2020 $20,405,099 $3,745,407 -$3,558,896 -1908% 01 Jan 2020 31 Mar 2020 20-F 21 Apr 2021 2020 FY
Q4 2019 $16,846,203 $7,830,025 01 Oct 2019 31 Dec 2019 20-F 16 May 2022 2021 FY
Q3 2019 $2,881,894 01 Jul 2019 30 Sep 2019 20-F 21 Apr 2021 2020 FY
Q2 2019 $5,947,773 +$2,074,423 +26% 01 Apr 2019 30 Jun 2019 20-F 21 Apr 2021 2020 FY
Q1 2019 $186,511 01 Jan 2019 31 Mar 2019 20-F 21 Apr 2021 2020 FY
Q2 2018 $8,022,196 -$7,702,180 -2407% 01 Apr 2018 30 Jun 2018 6-K 29 Aug 2019 2019 Q2
Q2 2017 $320,016 +$6,131,362 +95% 01 Apr 2017 30 Jun 2017 6-K 27 Sep 2018 2018 Q2
Q2 2016 $51,716,740 $6,451,378 -$5,110,610 -381% 01 Apr 2016 30 Jun 2016 6-K 10 Aug 2017 2017 Q2
Q1 2016 $46,606,130 $2,985,384 -$1,288,598 -76% 01 Jan 2016 31 Mar 2016 10-Q 12 May 2016 2016 Q1
Q4 2015 $45,317,532 $6,455,712 +$4,211,136 +188% 01 Oct 2015 31 Dec 2015 20-F 18 Jul 2018 2017 FY
Q3 2015 $49,528,668 $48,735,690 -$48,512,561 -21742% 01 Jul 2015 30 Sep 2015 10-Q 23 Nov 2015 2015 Q3
Q2 2015 $1,016,107 $1,340,768 +$888,232 +40% 01 Apr 2015 30 Jun 2015 6-K 14 Apr 2017 2016 Q2
Q1 2015 $1,904,339 $1,696,786 +$43,214 +2.5% 01 Jan 2015 31 Mar 2015 10-Q 12 May 2016 2016 Q1
Q4 2014 $1,947,553 $2,244,576 01 Oct 2014 31 Dec 2014 20-F 31 Mar 2017 2016 FY
Q3 2014 $223,129 01 Jul 2014 30 Sep 2014 10-Q 23 Nov 2015 2015 Q3
Q2 2014 $2,229,000 01 Apr 2014 30 Jun 2014 10-Q 12 Aug 2015 2015 Q2
Q1 2014 $1,740,000 01 Jan 2014 31 Mar 2014 10-Q 12 May 2015 2015 Q1

Akari Therapeutics Plc Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $19,791,000 -$9,783,000 -98% 01 Jan 2024 31 Dec 2024 10-K 15 Apr 2025 2024 FY
2023 $10,008,000 +$3,080,717 +24% 01 Jan 2023 31 Dec 2023 10-K 15 Apr 2025 2024 FY
2022 $13,088,717 +$4,335,520 +25% 01 Jan 2022 31 Dec 2022 8-K 06 Sep 2024
2021 $17,424,237 -$342,620 -2% 01 Jan 2021 31 Dec 2021 20-F 01 May 2023 2022 FY
2020 $17,081,617 -$235,414 -1.4% 01 Jan 2020 31 Dec 2020 20-F 01 May 2023 2022 FY
2019 $16,846,203 +$3,653,256 +18% 01 Jan 2019 31 Dec 2019 20-F 16 May 2022 2021 FY
2018 $20,499,459 +$14,899,798 +42% 01 Jan 2018 31 Dec 2018 20-F 21 Apr 2021 2020 FY
2017 $35,399,257 -$17,258,260 -95% 01 Jan 2017 31 Dec 2017 20-F 31 Mar 2020 2019 FY
2016 $18,140,997 +$27,176,535 +60% 01 Jan 2016 31 Dec 2016 20-F 23 Apr 2019 2018 FY
2015 $45,317,532 -$43,369,979 -2227% 01 Jan 2015 31 Dec 2015 20-F 18 Jul 2018 2017 FY
2014 $1,947,553 +$1,672,447 +46% 01 Jan 2014 31 Dec 2014 20-F 31 Mar 2017 2016 FY
2013 $3,620,000 +$648,000 +15% 01 Jan 2013 31 Dec 2013 10-K 11 Feb 2015 2014 FY
2012 $4,268,000 -$2,149,000 -101% 01 Jan 2012 31 Dec 2012 10-K 11 Feb 2015 2014 FY
2011 $2,119,000 -$1,444,000 -214% 01 Jan 2011 31 Dec 2011 20-F 24 Mar 2014 2013 FY
2010 $675,000 01 Jan 2010 31 Dec 2010 20-F 24 Mar 2014 2013 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.